Metaphedrine

{{Short description|Designer drug}}

{{Drugbox

| IUPAC_name = N-methyl-1-(3-methylphenyl)propan-2-amine

| image = 3-Methylmethamphetamine.svg

| image_class = skin-invert-image

| tradename =

| legal_DE =

| legal_UK =

| legal_US = Schedule I (isomer of Etilamfetamime)

| CAS_number = 861007-68-3

| PubChem = 24257262

| ChemSpiderID =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = ANT66P7LWF

| C=11 | H=17 | N=1

| smiles = CC1=CC(=CC=C1)CC(C)NC

| StdInChI = 1S/C11H17N/c1-9-5-4-6-11(7-9)8-10(2)12-3/h4-7,10,12H,8H2,1-3H3

| StdInChIKey = CXVNKBVJDKMLOH-UHFFFAOYSA-N

}}

3-Methylmethamphetamine (3-MMA) or Metaphedrine is an amphetamine derivative which has been sold as a designer drug, first being reported in Sweden in 2021.{{cite book | url = https://www.emcdda.europa.eu/system/files/publications/14637/20222218_PDF_TD0522113ENN_002.pdf | title = New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System | publisher = European Monitoring Centre for Drugs and Drug Addiction | date = June 2022 | isbn = 978-92-9497-737-3 | doi = 10.2810/882318 | author1 = European Monitoring Centre for Drugs and Drug Addiction. | doi-broken-date = 2024-11-02 }}